14:30:38 EDT Mon 16 Mar 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

T:MSCL - SATELLOS BIOSCIENCE INC. - https://satellos.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MSCL - T  0.110.04·10.070.110.05-0.93-8.571.972443810.93  10.93  9.7718.98  6.2414:12:09Mar 1015 min RT 2¢
TSX - T0.110.04·10.070.110.05-0.93-8.544.144524910.93  10.93  9.8718.98  6.2414:12:0915 min
NEO ATS - U 10.20-0.78-7.11.5151110.24  10.64  10.2010:49:1415 min
Alpha - A 9.94-1.04-9.52.8281910.61  10.61  9.9413:22:0215 min
Omega - O 10.03-0.95-8.74.4451810.30  10.52  10.0313:41:3115 min
CSE ATS - P 10.10-0.88-8.01.1111210.43  10.43  9.8813:23:2815 min
CXC - X 10.05-0.93-8.50.99910.52  10.52  9.9214:12:0915 min
CX2 - H 10.05-0.93-8.54.3431910.31  10.64  9.7714:12:0915 min
CXD - D 10.125-0.855-7.82.8282810.30  10.52  10.0911:39:4115 min
MatchNOW - M 10.986.56653    15 min
Lynx - Y 10.08-0.90-8.23.4341810.70  10.70  10.0413:50:1715 min
CS2 - S 10.980.0712    15 min

Recent Trades - Last 10 of 438
Time ETExPriceChangeVolumeBuyerSellerMarkers
14:15:34H10.07-0.919079 CIBC36 LatimerE
14:14:51H10.07-0.911079 CIBC36 LatimerE
14:12:09H10.05-0.9310079 CIBC79 CIBCK
14:12:09X10.05-0.9310079 CIBC79 CIBCK
14:12:09T10.05-0.931001 Anonymous1 AnonymousK
14:06:53M10.00-0.9810079 CIBC79 CIBC
14:06:52T10.04-0.941001 Anonymous79 CIBCK
14:04:09T10.06-0.921007 TD Sec79 CIBCK
14:01:14T10.09-0.891001 Anonymous1 AnonymousK
13:58:50M10.05-0.9310079 CIBC79 CIBC

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2026-03-10 07:00C:MSCL15.77News ReleaseSatellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
2026-02-24 07:00C:MSCL15.36News ReleaseSatellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
2026-02-18 07:00C:MSCL15.58News ReleaseSatellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
2026-02-17 07:00C:MSCL15.74News ReleaseSatellos to Participate in Upcoming Investor Conferences
2026-02-12 12:38C:MSCL15.77News ReleaseSatellos says first participant dosed in DMD study
2026-02-10 07:00C:MSCL15.00News ReleaseSatellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
2026-02-09 17:00C:MSCL15.00News ReleaseSatellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares
2026-02-06 20:11C:MSCL16.05Prospectus ApprovedSatellos Bioscience to list 4,455,445 more shares
2026-02-06 17:39C:MSCL16.05News ReleaseSatellos Bioscience prices $50-million (U.S.) offering
2026-02-06 08:59C:MSCL16.15News ReleaseCanadian Investment Regulatory Organization Trade Resumption - MSCL
2026-02-06 08:48C:MSCL16.15News ReleaseCanadian Investment Regulatory Organization Trading Halt - MSCL
2026-02-05 16:20C:MSCL16.15News ReleaseSatellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
2026-01-29 11:46C:MSCL1.22News ReleaseSatellos appoints Paone as chief development officer
2026-01-29 00:06C:MSCL1.22RollbackSatellos Bioscience 1:12 rollback
2026-01-28 16:29C:MSCL1.22News ReleaseSatellos completes 1:12 share rollback
2025-12-09 12:43C:MSCL0.65News ReleaseSatellos gets IND clearance for phase 2 SAT-3247 study
2025-11-25 07:00C:MSCL0.70News ReleaseSatellos to Participate in December Investor Conferences
2025-11-18 11:43C:MSCL0.74News ReleaseSatellos research published in Nature Comms
2025-11-14 11:30C:MSCL0.73News ReleaseSatellos spends $4M (U.S.) on R&D in Q3 2025
2025-11-14 08:09C:MSCL0.69SEDAR Interim Financial StatementsSEDAR Interim Financial Statements